UNSPSC 51183105: Gliflumide

This classification denotes an anti-diabetic agent with the molecular formula C25H29FN4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) USE67B01YN, chemically known as benzeneacetamide, n-((1s)-1-(5-fluoro-2-methoxyphenyl)ethyl)-4-(((5-(2-methylpropyl)-2-pyrimidinyl)amino)sulfonyl)- but more generally known as gliflumide, which bears US NIH Compound Identifier 197722. European Medicines Agency schedules Gliflumide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07924MIG.

UNSPSC 51183105 Gliflumide, a Commodity code, encompasses pharmaceutical supply agreements that state and local government health systems purchase through cooperative purchasing vehicles to stock institutional formularies and medication dispensaries. State and local procurement under this code centers on establishing master supply agreements for generic pharmaceuticals and over-the-counter products distributed through authorized wholesale channels, with pricing, product availability, compliance certifications, and supply-chain transparency driving vendor selection. Issuing bodies are primarily state procurement offices administering multistate cooperative purchasing alliances on behalf of participating state agencies, local health departments, and other member jurisdictions. Vendors must hold current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, maintain contractual relationships with designated authorized wholesalers, and submit detailed product specifications including National Drug Codes, SKUs, UPCs, packaging configurations, and manufacturing locations to qualify for award.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products (Solicitation S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026. The procurement establishes multiple contracts effective July 1, 2026, for a two-year term with optional extensions, distributing awarded products to participating state and local government facilities across Minnesota and Oregon through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Evaluation weights pricing competitiveness at 75 percent, with smaller weightings on fixed pricing (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). All products must be available in the marketplace by May 15, 2026, and vendors must carry professional liability and commercial general liability coverage of $2,000,000 and $5,000,000 per occurrence respectively.